The following is a summary of “Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201,” published in the February 2024 issue of Pulmonology by Cho et al.
This analysis focuses on the first-line cohort of the LASER201 study, assessing the effectiveness and safety of lazertinib 240 mg as an initial treatment for epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non–non-small-cell lung cancer (NSCLC). Forty-three patients with EGFR mutation-positive NSCLC, who had not undergone prior EGFR tyrosine kinase inhibitor (TKI) therapy, received once-daily lazertinib 240 mg. The primary endpoint was objective response rate (ORR), evaluated by a blinded independent central review, with secondary efficacy endpoints including duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), tumor shrinkage, and overall survival (OS). At the primary data cut-off (January 8, 2021), the ORR was 70 %, DCR was 86 %, and the median DoR was 23.5 months. The median PFS was 24.6 months. At the final cut-off (March 30, 2023), the median OS was not estimable, with OS rates at 36 months and 54 months of 66 % and 55 %, respectively.
Common treatment-related adverse events included rash, diarrhea, pruritus, and paresthesia, with mostly mild to moderate severity. No grade 3 or higher rash or pruritus events were reported, while grade 3 or higher diarrhea and paresthesia occurred in a small percentage of patients. This analysis demonstrates the sustained clinical benefits of lazertinib 240 mg in EGFR-mutated NSCLC patients initiating treatment, with a tolerable safety profile consistent with previous reports.
Source: sciencedirect.com/science/article/abs/pii/S0169500224000424